Other Events ·
AstraZeneca completed an exclusive global license agreement with Dizal Pharmaceutical for Zegfrovy (sunvozertinib)…
AZNAstrazeneca PLC
AstraZeneca completed an exclusive global license agreement with Dizal Pharmaceutical for Zegfrovy (sunvozertinib), acquiring worldwide rights to develop and commercialize the oral EGFR inhibitor. The transaction includes a $600 million upfront payment and up to $900 million in contingent milestone payments, plus tiered royalties on sales. Zegfrovy is approved in the US and China for second-line treatment of NSCLC with EGFR exon 20 insertion mutations, with a US launch planned for Q4 2026. A supplemental New Drug Application for first-line use has been accepted by the FDA, supported by Phase III WU-KONG28 data showing positive results. AstraZeneca is a global biopharmaceutical company focused on discovering and commercializing prescription medicines in oncology, rare disease, and other therapeutic areas.